TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35426778

Group type: EXPERIMENTAL
Intervention: Oral arginine supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 33648347

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 34670908

Group type: EXPERIMENTAL
Intervention: Ileal neobladder surgery
Number of subjects: 40
Study: 35031896

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 147
Study: 34130033

Group type: EXPERIMENTAL
Intervention: High n‐3 PUFA, average n‐6 PUFA (H3) diet targeting 1500 mg EPA+DHA/day and 7% of energy from n‐6 linoleic acid (LA)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High n‐3 PUFA, low‐n‐6 PUFA (H3L6) targeting 1500 mg EPA+DHA/day and <1.8 en% n‐6 LA
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control diet with typical American intakes of both EPA+DHA (<150 mg/day) and 7 en% from n‐6 LA
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High n‐3 PUFA, average n‐6 PUFA (H3) diet
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High‐n‐3 PUFA, low‐n‐6 PUFA (H3L6)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: All diet groups
Number of subjects: 178
Study: 35115574

Group type: EXPERIMENTAL
Intervention: IV Interferon (IFN) beta‐1a (10 μg) for 6 days after surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IV Interferon (IFN) beta‐1a
Number of subjects: 38
Study: 33479268

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 1 mmol L-1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 3 mmol L-1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cadmium (Cd) at 50 µmol L-1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cadmium (Cd) at 200 µmol L-1
Number of subjects: 9
Study: 32769643

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (50 units, injected twice, 3 months apart)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (injected twice, 3 months apart)
Number of subjects: 88
Study: 34462956

Group type: EXPERIMENTAL
Intervention: Synbiotic capsules (Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides) twice per day for 14 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Synbiotic capsules
Number of subjects: 38
Study: 34610580

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 193

Group type: COMPARATOR
Intervention: Paroxetine/Fluoxetine
Number of subjects: 193
Study: 35525480

Group type: EXPERIMENTAL
Intervention: BDP/FF 200/12 μg via DPI
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BDP/FF 400/24 μg via DPI
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BDP/FF 800/48 μg via DPI
Number of subjects: 36
Study: 35008055

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Amoxicillin (7-day course)
Number of subjects: 301
Study: 35001638

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33751409

Group type: EXPERIMENTAL
Intervention: mERAS
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study: 35793409

Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 32954807

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (PV) in combination with bendamustine and rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32094326

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) over the DMN
Number of subjects: 26
Study: 36127866

Group type: EXPERIMENTAL
Intervention: Mini-Subvastus Approach (MSVA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Medial Parapatellar Approach (MPA)
Number of subjects: 58
Study: 32464807

Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion (EVLP)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (standard criteria lungs)
Number of subjects: 216
Study: 34570990

Group type: EXPERIMENTAL
Intervention: Intracutaneous pyonex
Number of subjects: 88
Study: 34448089

Group type: EXPERIMENTAL
Intervention: PCV‐VG plus individual PEEP (PI group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PCV‐VG plus 5cmH2O PEEP (PF group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: VCV plus individual PEEP (VI group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: VCV plus 5cmH2O PEEP (VF group)
Number of subjects: 120
Study: 33711538

Group type: EXPERIMENTAL
Intervention: First method for generating synthetic SNPs based on the phenotype vector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second method for generating synthetic SNPs based on real SNPs similar to the phenotype vector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression for GWAS
Number of subjects: 0
Study: 35278807

Group type: EXPERIMENTAL
Intervention: Intensive telephone‐based intervention for smoking cessation after discharge
Number of subjects: 530
Study: 34898493

Group type: EXPERIMENTAL
Intervention: Educational intervention focusing on antimicrobial agents prescribing and resistance
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69
Study: 34504252

Group type: EXPERIMENTAL
Intervention: FiO2 of 0.5 to 1.0 (on-pump)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FiO2 of 0.3 to 0.8 (off-pump)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall FiO2 change of 0.5
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Residual ΔSvO2
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease status
Number of subjects: 53
Study: 32475183

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 36420908

Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 440

Group type: COMPARATOR
Intervention: Educational materials
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 440
Study: 34630609

Group type: EXPERIMENTAL
Intervention: Yiqi-Wenjing-Fang (YWF) granules (HGWD granules)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Yiqi-Wenjing-Fang (YWF) granules (DSD granules)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (mimetic granules of YWF)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All groups (YWF granules, HGWD granules, DSD granules, and placebo)
Number of subjects: 360
Study: 35059257

Group type: EXPERIMENTAL
Intervention: Electrolyzed hydrogen-rich water (EHW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Filtered water (FW)
Number of subjects: 50
Study: 33096554

Group type: EXPERIMENTAL
Intervention: Healthy diet (HD)
Number of subjects: 40
Study: 36429537

Group type: EXPERIMENTAL
Intervention: Technological rehabilitation (TG)
Number of subjects: 30
Study: 34280013

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600mg over 2h q8h (intermittent group)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600mg over 2h (loading dose) and 1200mg over 22h (continuous group)
Number of subjects: 9
Study: 32476619

Group type: EXPERIMENTAL
Intervention: Task-specific training (upright stepping)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impairment-based training
Number of subjects: 0
Study: 33564825

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (600 kcal energy, 20 g protein, and micronutrient supplementation daily)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 816
Study: 32759347

Group type: EXPERIMENTAL
Intervention: Venous sampling
Number of subjects: 113

Group type: COMPARATOR
Intervention: Arterial sampling
Number of subjects: 113
Study: 32186014

Group type: EXPERIMENTAL
Intervention: Jiawei Shenfu decoction
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard medications
Number of subjects: 63
Study: 34787647

Group type: EXPERIMENTAL
Intervention: Inhaled Epoprostenol (iEPO)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 201
Study: 33661070

Group type: EXPERIMENTAL
Intervention: Conjunctival swab
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Slit-lamp examination
Number of subjects: 45
Study: 36076163

Group type: EXPERIMENTAL
Intervention: Nomogram predicting cancer-specific survival (CSS) based on multivariate Cox regression model
Number of subjects: 14138
Study: 33840769

Group type: EXPERIMENTAL
Intervention: Machine-based hand massage therapy (experimental group)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 199
Study: 35346044

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (combined with ropivacaine)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fentanyl (combined with ropivacaine)
Number of subjects: 61
Study: 32520602

Group type: EXPERIMENTAL
Intervention: Indirect laryngeal biopsy forceps combined with antibiotics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 20
Study: 32272255

Group type: EXPERIMENTAL
Intervention: Crushed prasugrel tablets
Number of subjects: 674

Group type: COMPARATOR
Intervention: Integral prasugrel tablets
Number of subjects: 674
Study: 36258219

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Casirivimab + Imdevimab
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 45000
Study: 33300756

Group type: EXPERIMENTAL
Intervention: Fast-start (FS) phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Even-pace (EP) phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: End-spurt (ES) phase
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of phases
Number of subjects: 12
Study: 32900785

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg once daily for 8 weeks)
Number of subjects: 46
Study: 36270742

Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 138
Study: 32776296

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Singing intervention
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 34821437

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) target group
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 290
Study: 32101157

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) bariatric surgery
Number of subjects: 80
Study: 33636616

Group type: EXPERIMENTAL
Intervention: Higher seasonally adjusted 25(OH)D levels
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels during spring
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Seasonally adjusted 25(OH)D levels below 80 nmol/L
Number of subjects: 88

Group type: COMPARATOR
Intervention: BMI and cotinine
Number of subjects: 88
Study: 33951350

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 63

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 63
Study: 32767414

Group type: EXPERIMENTAL
Intervention: Feru-guard 100M (daily for 48 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 17
Study: 36014906

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 10
Study: 34501916

Group type: EXPERIMENTAL
Intervention: EC 50%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EC 100%
Number of subjects: 14
Study: 33242020

Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone app and smart band)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard counselling (control group)
Number of subjects: 440
Study: 33565409

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (30 minutes, twice daily) on Zusanli, Tianshu, Shangjuxu, Xiajuxu, and Zhongwan, in addition to conventional western medicine for 7 days.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional western medicine treatment for 7 days.
Number of subjects: 100
Study: 35555246

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2: 0.10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2: 0.50)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 22
Study: 33999414

Group type: EXPERIMENTAL
Intervention: Placebo treatment - participants learned of a mood-enhancing treatment and received it
Number of subjects: 125

Group type: COMPARATOR
Intervention: Treatment deprivation - participants learned of the same treatment, but did not receive it
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control - treatment was never mentioned
Number of subjects: 125
Study: 36540062

Group type: EXPERIMENTAL
Intervention: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin (single dose or three consecutive days)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin
Number of subjects: 1097

Group type: COMPARATOR
Intervention: 400 mg albendazole (control)
Number of subjects: 1097
Study: 33545772

Group type: EXPERIMENTAL
Intervention: DPE + PIEB
Number of subjects: 200

Group type: COMPARATOR
Intervention: CEI + PIEB
Number of subjects: 200
Study: 32969884

Group type: EXPERIMENTAL
Intervention: Gunsight procedure
Number of subjects: 143

Group type: COMPARATOR
Intervention: Purse-string procedure
Number of subjects: 143
Study: 33969955

Group type: EXPERIMENTAL
Intervention: Mild hyperbaric oxygen (MHO) at 1.3 atmospheres absolute with 31% oxygen for 60 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON) trial for 60 min recovery
Number of subjects: 10
Study: 32628582

Group type: EXPERIMENTAL
Intervention: Generic pegaspargase (Hamsyl)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reference pegaspargase (Oncaspar)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (Generic and Reference pegaspargase)
Number of subjects: 29
Study: 35705671

Group type: EXPERIMENTAL
Intervention: RIT-BFR
Number of subjects: 20

Group type: COMPARATOR
Intervention: RIT
Number of subjects: 20
Study: 33822134

Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide followed by weekly paclitaxel (EC-wP)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Epirubicin and paclitaxel followed by weekly paclitaxel (EP-wP)
Number of subjects: 521
Study: 35417857

Group type: EXPERIMENTAL
Intervention: Meniscus suturing with ACL plastic surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Meniscus resection with ACL surgery
Number of subjects: 66
Study: 32126851

Group type: EXPERIMENTAL
Intervention: Cemented dual-mobility cup (DMC) replacement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cemented 32-mm head total hip replacement (THR)
Number of subjects: 62
Study: 32873258

Group type: EXPERIMENTAL
Intervention: Multicomponent short break intervention
Number of subjects: 360
Study: 33347874

Group type: EXPERIMENTAL
Intervention: Active food preparation (making a wrap)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Passive video preparation (watching video of researcher making a wrap)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Distraction (a non‐food colouring task)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No time control
Number of subjects: 80
Study: 32450917

Group type: EXPERIMENTAL
Intervention: Intravenous Plasma-Lyte 148 (Plasmalyte)
Number of subjects: 800

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 800
Study: 34799534

Group type: EXPERIMENTAL
Intervention: Duodenal infusion of capsaicin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Capsaicin infusion
Number of subjects: 26
Study: 34640398

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg (CAF-9)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine 12 mg/kg (CAF-12)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of CAF-9 vs. CAF-12
Number of subjects: 12
Study: 34180246

Group type: EXPERIMENTAL
Intervention: Symptom minimizers (High KCCQ‐CS and high VE/VCO2 slope)
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Symptom magnifiers (Low KCCQ‐CS and low VE/VCO2 slope)
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Concordant-lower severity participants (High KCCQ‐CS and low VE/VCO2 slope)
Number of subjects: 2062
Study: 35930542

Group type: EXPERIMENTAL
Intervention: Community Assets Supporting Transitions (CAST) intervention
Number of subjects: 0
Study: 32293514

Group type: EXPERIMENTAL
Intervention: PROUD intervention for increasing medication treatment of opioid use disorders (OUDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary analyses including patients newly diagnosed post-randomization
Number of subjects: 0
Study: 35641822

Group type: EXPERIMENTAL
Intervention: Ahmed’s suture modified NPDS
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional NPDS
Number of subjects: 103
Study: 34380498

Group type: EXPERIMENTAL
Intervention: Training program for mothers of preterm infants
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 32298279

Group type: EXPERIMENTAL
Intervention: Anxiety Proneness (AP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study: 35063963

Group type: EXPERIMENTAL
Intervention: Levosimendan (12.5 mg single dose after induction of anaesthesia)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (single dose after induction of anaesthesia)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 33670999

Group type: EXPERIMENTAL
Intervention: Coconut oil supplementation (EVCO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 34726747

Group type: EXPERIMENTAL
Intervention: Individualized recommendations
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 32931684

Group type: EXPERIMENTAL
Intervention: Information only (IO) group received text messages with HIV prevention information.
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Information plus (IP) group received text messages and could win incentives by answering quiz questions and testing for HIV.
Number of subjects: 218

Group type: COMPARATOR
Intervention: Comparison group (nonrandomized)
Number of subjects: 218
Study: 34229315

Group type: EXPERIMENTAL
Intervention: ChRmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: ChrimsonR
Number of subjects: 0
Study: 35762489

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 426

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 426
Study: 33359379

Group type: EXPERIMENTAL
Intervention: Elastic Band Resistance Training (EBRT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dumbbell Resistance Training (DBRT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 65
Study: 32729342

Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion and chorion allograft (dHACA) plus standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study: 34743530

Group type: EXPERIMENTAL
Intervention: 30 months of DAPT after coronary stent procedures
Number of subjects: 568540
Study: 34050972

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab (Ven-Obi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil-obinutuzumab (Clb-Obi)
Number of subjects: 0
Study: 35796669

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 32
Study: 34055704

Group type: EXPERIMENTAL
Intervention: Health coaching and usual care
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 114
Study: 35604744

Group type: EXPERIMENTAL
Intervention: OROS‐MPH (osmotic‐release oral system methylphenidate)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 33935094

Group type: EXPERIMENTAL
Intervention: B-vitamins (folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 34971816

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 160
Study: 32871328

Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 1923
Study: 35896694

Group type: EXPERIMENTAL
Intervention: QL1206 (60 mg subcutaneously every 6 months)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 34670396

Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy
Number of subjects: 0
Study: 33006997

Group type: EXPERIMENTAL
Intervention: Intervention group (IPV prevention intervention)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 425
Study: 36041669

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 33390325

Group type: EXPERIMENTAL
Intervention: EP0057 (15 mg/m2 Q2W) plus paclitaxel (80 mg/m2, 3 weeks on/1 week off)
Number of subjects: 30
Study: 33073501

Group type: EXPERIMENTAL
Intervention: Experimental group (sympathetic nerve fibers in ligamentum flavum)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (cadaver specimens)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sympathetic nerve fibers distribution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1H-NMR analysis of LF spinal canal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Follow-up of patients with vertebral artery dissection
Number of subjects: 15
Study: 34984791

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304